



Cracking the code for continuous processing and 
personalised medicine
Summary of the impact:
Personalised medicine is the next great 
global challenge for the pharmaceutical 
industry. The vision of the pharmacy of the 
future is one in which pharmacies employ 
disruptive technologies to enable on-demand 
manufacture of drugs designed to individual 
needs. For example, multiple medications 
may be prescribed that treat a patient’s 
exact age-profile and medical history. These 
medications could then be 3D printed into 
one tablet, on-demand at the patient’s local 
drug supplier.
Researchers led by Prof Gavin Walker at the 
Bernal Institute, University of Limerick (UL), 
are generating the chemical engineering 
solutions for the challenges of personalised 
medicine. This highly cited research is 
changing how we train chemical engineers, 
impacting industry competitiveness, and 
attracting R&D investment into Ireland. 
Underpinning research:
Pharmaceutical manufacturing is a vital 
facet of the Irish economy. It is responsible 
for more than 50 percent of exports and 
employs over 50,000 people directly and 
indirectly. Over the last ten years,   the 
industry in Ireland has made more than 
€10,000 million worth of capital investment 
in facilities. It is a highly advanced sector. In 
many cases, major companies have made 
significant repeat investments. This supports 
the strong reputation that Ireland has built up 
in this sector, as a country with an excellent 
regulatory track record and available talent. 
The Irish-based operations of multinational 
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Central to this vision is the concept of 
continuous processing. Currently, active 
pharmaceutical ingredients (APIs) are 
manufactured in large batches at distinctly 
separate times. Continuous processing 
replaces this large-batch process with 
the manufacture of lower volumes but 
at a constant rate. This process enables 
the continuous flow of product, reduces 
inventories, and has less batch-to-batch 





companies (MNCs) are increasingly aware of 
the need to improve their value proposition to 
their corporate headquarters. Successful late 
stage and commercial R&D is highly prized 
and a signal of long-term investment for Irish 
MNC operations.  Research into engineering 
solutions that deliver personalised medicine 
has the potential for world-wide impact on 
the pharmaceutical industry. This research is 
a particular ambition for Irish pharmaceutical 
R&D. 
Over the past five years, Professor Gavin 
Walker, Bernal Chair of Pharmaceutical 
Powder Engineering, has been tackling the 
challenge of continuous processing to enable 
personalised medicine. Prof Walker leads the 
Bernal Process Engineering Lab at the Bernal 
Institute, UL, a lab funded by Enterprise Ireland 
and Science Foundation Ireland. It hosts three 
national research centres: the Synthesis and 
Solid State Pharmaceutical Centre (SSPC); the 
Pharmaceutical Manufacturing Technology 
Centre (PMTC); the Dairy Processing 
Technology Centre (DPTC). The award-
winning lab1  is home to an international 
team of 35 researchers from 12 countries. The 
purpose-built facility provides a one-of-its-
kind environment within Ireland; it is the only 
academic lab with an industrial scale, fully-
ventilated laboratory space and state-of-the-
art analytical equipment. Both wet and dry 
chemistry facilities are available and the lab 
operates industry-standard quality systems 
(to the 5S standard). In this environment, 
industry can be confident the solutions 
provided meet global standards. In addition, 
the availability of industrial-size equipment 
ensures that solutions are brought quickly to 
the factory-floor. For example, the timeline 
for Enterprise Ireland research technology 
transfer from the Lab to Industry is typically 
6-12 months.  
Furthermore, it is widely recognised across 
academia and industry that the future 
manufacture of medicine will be multi-
disciplinary. For example, it may involve 
autonomous, local machines in the corner 
of a distributing pharmacist or lab, where 
medicines are printed on-demand to exact 
medical profiles.  Such manufacture requires 
research at UL to be also multi-disciplinary 
and this has already begun. UL is leading 
innovation in crucial areas, such as chemistry 
(Ref 1, 2), process engineering (Ref 3–7), data 
analytics (Ref 8), and mathematical modelling 
(Ref 9). 
In addition, given the rise of connected devices 
and big data, the pharmaceutical industry 
requires manufacturing systems that have full 
feedback control or are self-correcting. This 
requires the lab’s research activities to advance 
process modelling (Ref 10), process analytic 
technology (PAT) (Ref 11, 12), and statistical 
modelling (Ref 13), especially for predictive 
control of pharmaceutical manufacturing (Ref 
14, 15). Connected devices and big data also 
allow medicine manufacturers to reduce the 
time to market in drug development.  The 
lab’s research is improving the efficacy of 
drug products (Ref, 16, 17) and addresses the 
special needs of new, more complex active 
ingredients for specific patient groups (Ref 18 
– 20). 
As well as contributions to basic research, 
such as international journal publications, 
our research has led to the commercialisation 
of the continuous pharmaceutical 
manufacturing technologies developed at UL 
(Ref 21-26).  For example, we have created a 
spin-out UL company Innovative Powder 
Processing (iP2) that efficiently connects 
novel academic research to the commercial 
R&D industry. Through IPP, we have a number 
of invention disclosures (Ref 27-28) and a 
patent pending (Ref 29).   
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National awards arising from the research 
include: Irish Lab Award: Chemical Lab of 
the Year (2017); Pharmaceutical Lab of the 
Year at the Irish Lab Awards (2017); Research-
Academic Lab of the Year (2017).  
Details of the impact 
Three of the most important impacts from 
this body of research are on industry through 
disruptive technologies driving innovation 
and growth, regional R&D through increased 
investment, and academia through new 
programmes and more informed practice. 
Prof Walker and his team have forged long-
standing partnerships with industry that, 
through PMTC and SSPC, have led to new 
product developments, greater efficiencies, 
and quality standards across multinational 
and SME firms. New technologies that PMTC 
implements, in close cooperation with other 
enterprises, MNCs and PMTC, also enable 
SMEs to strengthen their capacity and 
ability to drive innovation through research 
and development (R&D). PMTC enables 
SMEs to be part of a cluster or ecosystem 
of companies, clients and researchers. 
This membership reduces the barriers to 
innovation, collaboration and R&D and 
provides a neutral ground for meeting clients 
and suppliers. 
For example, Luke Kiernan of the Irish 
SME Innopharma Labs states that, for their 
successful European Commission SME 
award of €2.3 million, “Innopharma labs have 
benefitted from our strong involvement in 
Prof Walker’s group and having an academic 
case study on a successful continuous 
pharmaceutical processing was extremely 
useful for our successful H2020 submission”. 
(Source 1)
Through the SSPC MOMEnTUM Spoke project 
hosted by the Bernal Process Engineering 
Laboratory, the team are working closely 
with leading corporate technical staff from 
Johnson & Johnson, linking sites across 4 
countries: Puerto Rico, US, Belgium, and 
France. This collaboration is described 
as “the foundational enablement for 
manufacturing of the future” with impacts on 
understanding of science and engineering in 
the development of emerging technologies 
which supports industry to become more 
innovative. (Source 2) 
The research findings inform professional 
training and quality standards in the 
pharmaceutical industry. Prof Walker and 
Dr Albadarin have contributed to the 
establishment of the Specialist Diploma in 
Regulatory Affairs, a diploma developed with 
input from the Health Products Regulatory 
Authority and BioPharmaChem Ireland 
experts. The programme is developed in 
response to industry need and a strong 
demand in Ireland for regulatory affairs 
professionals for the pharmaceutical 
industry.  Through a series of masterclasses, 
the team contributes to upskilling the Irish 
pharmaceutical sector, instilling a better 
understanding of patient impact. 
Greg Donegan, senior scientist at Roche, 
explains: “Coming from a drug substance 
background and with little to no exposure 
of the concepts and issues faced in the 
drug product world”, taking Industrial 
Pharmaceutical Master Classes facilitated 
by Prof Walker’s Bernal Process Engineering 
Laboratory he “gained a lot of understanding 
about how drug product formulation is 
crucial to patients’ wellbeing. This was 
shown both theoretically in the presentations 
and practically with the demonstrations of 
different types of equipment”. 
He adds that “some of the PAT techniques 
were particularly interesting”, especially as 
PAT “plays an important role for us in the 
drug substance part of Roche”. (Source 3) 
PMTC’s impact on technological innovation 
in industry, regional investment, and 
academia will continue and deepen 
through its recently-awarded MCSA/
European Commission co-funded fellowship 
programme PROCESS. PROCESS is a five-
year programme with the overall theme 
of advanced manufacture of high value 
products and engineering solutions for 
related industries. Its particular emphasis is 
on particulate product processing for new 
products in the dairy and pharmaceutical 
sectors. The programme is envisaged 
to be multi-disciplinary, for example, 
including process modelling and smart data 
management, and international, recruiting 
up to 26 research fellows from several 
nationalities. It also engages with the larger 
industry and academic community outside 
UL, requiring fellows to take secondments in 
the dairy and pharmaceutical businesses as 
well as other related research centres. 
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